When joints hurt during breast-cancer endocrine therapy, “exercise more” can sound dismissive. A better conversation asks what kind of movement was tested, how much relief people experienced, and what support made participation possible. Exercise belongs in that conversation, but pain should not be treated as a test of motivation.
Evidence at a glance
Population: Previously inactive women with breast cancer and joint pain while taking an aromatase inhibitor. Intervention: Aerobic activity plus supervised resistance training. Signal: A positive yearlong trial, alongside uncertain pooled evidence. Boundary: Symptom improvement is not proof of better endocrine-treatment adherence, reduced recurrence or longer survival.
What the HOPE trial found
The HOPE randomized trial, published in 2015, enrolled 121 women taking an aromatase inhibitor for at least six months. They reported worst joint pain of at least 3 out of 10 and little regular exercise. The study compared usual care with a program targeting 150 minutes of aerobic activity weekly and supervised strength training twice weekly for a year. This describes the research program, not a starting prescription for every reader.
At 12 months, worst pain decreased by 1.6 points, or 29%, with exercise, while increasing by 0.2 points with usual care. That is an approximately 1.8-point difference in change on a 0–10 scale. The average reduction could matter in daily life, but it does not mean everyone improved by that amount. Participants attended about 70% of resistance sessions; perfect adherence was not required.
Why the reviews are more cautious
A 2020 Cochrane review included seven studies and 400 women. It found low- or very-low-certainty evidence and could not establish a clear overall pain benefit. Exercise programs, comparisons and follow-up periods varied. Effects on continuing aromatase-inhibitor medication were uncertain, and survival data were absent.
A narrower December 2025 meta-analysis included three trials with 297 participants. Its overall pooled result was also not statistically significant, although a subgroup of aerobic-exercise studies favored exercise. With so few studies and substantial differences between them, that subgroup is a clue—not a definitive ranking of which exercise works best.
These findings can coexist. A particular supported program can help in one trial while the combined literature leaves uncertainty about the average benefit across different programs. The honest conclusion is neither “exercise cures the pain” nor “exercise is pointless.”
Build a plan around function
The American Cancer Society’s hormone-therapy guidance includes exercise among options for joint symptoms, alongside selected medicines, acupuncture or changes in endocrine therapy. Those choices belong in a discussion with the treating team. Do not stop the aromatase inhibitor independently.
An achievable goal might be getting out of a chair more comfortably or returning to a valued walk. Ask an oncology rehabilitation professional to help adapt the starting workload, especially with balance problems, neuropathy, recent surgery or bone fragility. New focal pain, marked swelling or difficulty bearing weight deserves assessment rather than an instruction to push harder.
Practical questions for the care team
Does this pain pattern fit the medication, or should another cause be assessed? Would supervised physical therapy or an exercise-oncology program help? How should bone health and other treatment effects shape the plan? Which pain and function measures should we track, and when should we reconsider if progress stalls?
Movement is one option in supportive care, not an obligation to tolerate uncontrolled pain. A plan that is safe, accessible and revisited is more useful than a demanding target handed over without support.
Evidence checked October 19, 2026. Educational review, not individualized medical advice. Research doses and schedules are not personal prescriptions. Explore the Missing Script article library and the podcast—coming soon.
